Abivax (ABVX) to Post Quarterly Earnings on Monday

Abivax (NASDAQ:ABVX) will likely be releasing its Q2 2026 results after the market closes on Monday, September 21st. Analysts expect the company to announce earnings of ($0.9170) per share and revenue of $0.7990 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, September 21, 2026 at 11:40 AM ET.

Abivax Price Performance

Shares of ABVX opened at $105.04 on Friday. The firm has a 50-day moving average of $121.41 and a 200-day moving average of $117.69. The company has a market cap of $9.16 billion, a PE ratio of -20.16 and a beta of 0.96. Abivax has a one year low of $69.81 and a one year high of $148.83.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ABVX shares. HC Wainwright reaffirmed a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. Guggenheim reiterated a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. The Goldman Sachs Group assumed coverage on Abivax in a report on Wednesday, September 9th. They set a “buy” rating and a $155.00 price objective on the stock. Piper Sandler boosted their price objective on Abivax from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Finally, Jefferies Financial Group raised Abivax from a “hold” rating to a “buy” rating and upped their target price for the stock from $108.00 to $158.00 in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $156.38.

Abivax Company Profile

Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.

Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn’s disease.